. NADHox and ROS were measured with the use of lucigenin chemiluminescence and electron spin resonance, respectively. In myocardial homogenates, pyruvate (0.05, 0.5 mM) and the NADHox blocker hydralazine markedly inhibited NADHox (16 Ϯ 2%, 58 Ϯ 9%). In postischemic hearts, pyruvate (0.1-5.0 mM) dose dependently inhibited ROS up to 80%. However, L-lactate (1.0-15.0 mM) stimulated both basal and postischemic ROS severalfold. Furthermore, L-lactate-induced basal ROS was dose dependently inhibited by pyruvate (0.1-5.0 mM) and not the xanthine oxidase inhibitor oxypurinol. Pyruvate did not inhibit ROS from xanthine oxidase. The data suggest a substantial influence of cytosolic NADH on cardiac O 2 Ϫ ⅐ formation that can be inhibited by submillimolar pyruvate. Thus cytotoxicities due to cardiac ischemia-reperfusion ROS may be alleviated by redox reactants such as pyruvate.
reduced nicotinamide adenine dinucleotide oxidase; heart; ischemia-reperfusion MANY DISEASE STATES (atherosclerosis, hypercholesterolemia, hypertension, diabetes, ischemia-reperfusion injury, inflammation, congestive heart failure) are known to be associated with enhanced production of reactive oxygen species (ROS) and plasma lactate levels. Increased ROS formation may also reduce levels of vasodilator nitric oxide and enhance formation of the cytotoxic peroxynitrite (12) . Oxidoreductases such as the membrane-associated NADH oxidase contribute to ROS formation in isolated cardiomyocytes (19 (2, 5) . The redox state of cytoplasmic NADH closely correlates with the tissue pyruvate concentration-to-L-lactate concentration ratio ([pyruvate]/ [L-lactate]). Sustained changes in redox reactants such as pyruvate or L-lactate may be associated with altered activity or expression of lactate dehydrogenase (LDH) and glutathione peroxidase (7) and can also affect the antioxidant status of the glutathione system, i.e., the ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) (25) .
In the present study, we imposed cytosolic redox changes using exogenous pyruvate or L-lactate. We tested the hypothesis that ROS formation, if mediated via extramitochondrial tissue NADH oxidase activity, would be inhibited by pyruvate and stimulated by L-lactate, consistent with the concept of redox control of the NADH oxidase by the cytosolic NADH/NAD ϩ system. The dose-response relations between NADH oxidase activity and exogenous pyruvate were quantitated in crude homogenates of heart, liver, and aorta and compared with those of the known oxidase inhibitor hydralazine (8) . We also established the full doseresponse effects of pyruvate versus L-lactate on ROS production in intact perfused hearts that were subjected to a brief 5-min ischemia-reperfusion protocol. We observed striking dose-dependent inhibitions of cardiac NADH oxidase and postischemic ROS formation by pyruvate, even when applied in submillimolar near-physiological concentrations.
METHODS
Heart preparation. The hearts of ketamine (100 mg/kg im)/xylazine (4 mg/kg im)-anesthetized guinea pigs were quickly isolated and perfused at constant flow with a KrebsHenseleit solution containing (in mM) 5.5 glucose, 1.25 CaCl 2 , 120 NaCl, 25 NaHCO 3 , 1.2 MgSO 4 , 1.2 NaH 2 PO 4 , and 4 KCl, equilibrated with 95% O 2 -5% CO 2 (pH 7.4) at 37°C. Initial perfusion rate was set so that perfusion pressure was 60 mmHg. During the course of the experiments, perfusion rate was held constant at 11 ml/min, and pressures varied between 55 and 65 mmHg, well within the coronary flow autoregulatory range of the guinea pig heart (11) . After an initial stabilization period of 20 min, hearts were electrically paced at 250 beats/min. The protocol conformed to the National Research Council's Guide for the Care and Use of Laboratory Animals.
Five-minute ischemia-reperfusion protocol. After the initial stabilization period of 20 min, the paced hearts were subjected to a control ischemia-reperfusion period composed of 5 min of zero-flow ischemia followed by 25 min of reperfusion (Fig. 1, period I) . During the last 15 min of the first reperfusion, pyruvate, L-lactate, or no additional substrate was added to the perfusion medium followed by a second ischemia-reperfusion period (Fig. 1, period II) in which redox parameters were altered as indicated. Coronary effluent samples for determination of ROS (see below) were collected every 10 s during the first minute of reperfusion; thereafter, samples were collected at 1-min intervals. Time controls (n ϭ 3) showed no appreciable differences between the two periods in terms of the postischemic ROS release (data not shown); this indicated that the first 5-min ischemia-reperfusion period I did not precondition the myocardium against ROS production in period II.
ROS release in perfused hearts measured by electron spin resonance. Cardiac ROS formation was determined in the presence or absence of different concentrations of the redox reactants L-lactate and pyruvate. The new spin trap 1-hydroxy-3-carboxy-pyrrolidine (CP-H) was used as detailed previously; this technique records oxyradicals, O 2 Ϫ ⅐ (superoxide radical), ONOO Ϫ (peroxynitrite), and ⅐OH (hydroxyl radical), with a rate constant of 3.2 ϫ 10 3 M Ϫ1 ⅐ s Ϫ1 when O 2 Ϫ ⅐ reacts with the spin trap CP-H (8). CP-H concentration in the perfusate was 0.8 mM; 50 M desferoxamine was added to minimize formation of radicals due to trace amounts of transition metals of the perfusion buffer. The stable paramagnetic reaction product, 3-carboxy-proxyl, was identified and quantitated by electron spin resonance (ESR) spectroscopy with the use of an EMX-A spectrometer (Bruker, Karlsruhe, Germany). The ESR settings were as follows: modulation frequency, 30 Hz; receiver gain, 10 5 ; microwave power, 20 mW; microwave frequency, 9.72 GHz; modulation amplitude, 1 G; conversion time, 327 ms; detector time constant, 655 ms; field sweep, 60 G; and center field, 3,474 G. Calibration of the ESR spectrometer was carried out with the use of standards supplied by the manufacturer.
Potential underestimation of ROS using CP-H spin traps in presence of pyruvate versus L-lactate. O 2
Ϫ ⅐ was generated by xanthine (200 M)/xanthine oxidase (2-10 mU/ml) (X/XO) in potassium phosphate buffer (10 mM, pH 7.4, 37°C) containing 50 M desferoxamine. The system was free from NADH and LDH. ESR quantification of ROS was done with the use of 0.7 mM CP-H as scavenger in the presence or absence of pyruvate (5-10 mM) or lactate (5 mM). Activity of the O 2 Ϫ ⅐ generator was ascertained by use of 1 mM oxypurinol, which completely inhibited the reaction (data not presented).
Cytosolic versus mitochondrial sites of the antioxidant feature of pyruvate. To differentiate between mitochondrial and cytosolic antioxidant effects of pyruvate under conditions of the increased oxidant stress of reperfusion, we used 0.5 mM ␣-cyano-3-hydroxycinnamate (n ϭ 2) to selectively inhibit mitochondrial pyruvate uptake in the guinea pig heart (3) without affecting plasmalemmal monocarboxylate transport or cytosolic pyruvate metabolism (17) .
Contribution of XO to cardiac ROS formation. Guinea pig coronary endothelium has XO, the activity of which could contribute to ROS release from the whole heart. To assess the possible contribution of xanthine-xanthine dehydrogenase/ oxidase (X/XO) to total cardiac ROS formation, the effects of the X/XO inhibitor oxypurinol (0.1-0.5 mM) were measured in hearts the ROS production of which was stimulated by 10 mM L-lactate. Separate experiments demonstrated that 0.1 mM oxypurinol inhibited the activity of commercially available xanthine dehydrogenase (XOD; 0.05 U) by 80%.
NADH oxidase activities in crude homogenates of myocardium, aorta, and liver. The activities of NADH oxidase (NADHox) were measured in crude homogenates prepared by pulverization of frozen tissue with a dismembranator (Braun, Melsungen, Germany). ROS formation in 10-mg homogenate samples was measured with the use of 0.25 M lucigenin according to Allen (1) in 10 mM HEPES buffer, incubated with 100 M NADH. A microplate luminometer (Berthold, Pforzheim, Germany) was used to measure the chemiluminescence intensity. For calibration, X/XO (80 mM/ 0.05 U) was used.
All chemicals except CP-H (Alexis, San Diego, CA) were purchased from Sigma (Deisenhofen, Germany).
Statistics and fitting nonlinear kinetics. Data are expressed as means Ϯ SE. Student's t-tests for unpaired samples with P Ͻ 0.05 were considered significant.
Nonlinear data sets (Figs. 2 and 3) were fitted iteratively by use of the maximum likelihood method (11) . In the homogenate analyses (Fig. 2) , regression coefficients were estimated assuming rectangular hyperbolic kinetics %inhibition ϭ ͓pyruvate͔/͑␣ ⅐ ͓pyruvate͔ ϩ ␤͒ where 1/␣ is maximum inhibition, ␤ is rate constant, and ␤/␣ is the half-maximal effective concentration. Unlike the classical double-reciprocal approach, hyperbolic models are defined for zero agonist concentration, which improves precision of fits. Regression coefficients Ϯ SE values were estimated by use of the Newton-Raphson algorithm. Confidence in estimated SE values was obtained by residual analyses, as detailed elsewhere (11) .
Postischemic ROS release ( Fig. 3 ) was fit by use of a lognormal function rate of ROS release ͑% of basal rate͒
where a 1 , a 2 , and a 3 are the coefficients to be estimated and x is the time elapsed during reperfusion in seconds. Total extra ROS released during postischemia was obtained by Figure 2 shows that exogenously added pyruvate produced a concentration-dependent inhibition (0.05-50 mM) of ROS formation. The sigmoid inhibition patterns demonstrated that 0.05 mM pyruvate, a subphysiological concentration, modestly but significantly attenuated ROS formation (15 Ϯ 1.5%). However, even at the extreme dose of 50 mM, pyruvate did not completely inhibit ROS formation of the homogenates. From the fits, it was estimated that the maximum ROS inhibition by pyruvate was 58.3 Ϯ 7%, significantly less than 100%. At cardioprotective concentrations between 1 and 5 mM (9, 13, 24), pyruvate inhibited ROS formation in homogenates by ϳ55%. Furthermore, Fig.  2 shows that pyruvate was also an effective inhibitor of ROS formation in homogenates from aorta and liver.
RESULTS

Effects of pyruvate on homogenate ROS formation.
In a separate series of experiments, we analyzed dose-response relations between hydralazine, an inhibitor of NADHox in rabbit aorta (21) , and NADHox in heart homogenates. Hydralazine also caused dose-dependent decreases in oxidase activities in guinea pig heart homogenates. Threshold concentrations for ROS inhibition were near 0.08 mM; maximum inhibitions were below 100% and occurred near 8 mM (78 Ϯ 7.8%, n ϭ 6; data not shown). Thus the pyruvate inhibition kinetics of Fig. 2 compared well with those obtained with hydralazine: with both agents, threshold inhibitory doses were around 0.1 mM, and maximum inhibitions were approached at concentrations between 5 and 10 mM. Neither agent was able to completely inhibit ROS formation. Thus the NADHox inhibition kinetics due to pyruvate compared well with those due to hydralazine. Pyruvate was nearly as powerful an inhibitor of homogenate ROS formation (and hence inferred NADHox activity) as hydralazine in the guinea pig cardiac homogenates.
Effects of pyruvate versus L-lactate on pre-and postischemic cardiac ROS formation. Pyruvate markedly inhibited ROS formation in postischemic hearts. Quantitative data are depicted in Fig. 3 . In the absence of pyruvate, peak ROS release after a brief 5-min period of zero-flow ischemia occurred ϳ12 s after start of reperfusion. With increased perfusate pyruvate concentrations, time to peak ROS release appeared to increase, whereas peak height decreased. Within 60 s, postischemic ROS formation reached preischemic control levels. A smooth lognormal function fits the data readily and with high precision (Fig. 3 and see METH-ODS).
After integration of the postischemic ROS release functions, pyruvate inhibition of the reperfusion burst in ROS formation was expressed as 1 Ϫ (total measured release/total uninhibited ROS release) and plotted as a percentage against the perfusate pyruvate level (Fig. 3) . A 25% decrease of total postischemic ROS occurred at 0.11 Ϯ 0.001 mM pyruvate, and a 50% decrease occurred at 0.81 Ϯ 0.001 mM pyruvate. At 6.15 Ϯ 0.0024 mM, pyruvate inhibited postischemic ROS by 75% (not 100%), which compared with the 58% Fig. 3 . Dose-dependent inhibition by pyruvate of postischemic reactive oxygen species (ROS) production in constant-flow (11 ml/min) perfused guinea pig hearts. A value of 100% represents basal release before pyruvate infusion and the 5-min zero-flow ischemia. A significant (P Ͻ 0.05) suppression of postischemic ROS formation was obvious within the first 10 s of reperfusion (near peak ROS release) with physiological pyruvate concentrations near 100 M. Inset: pyruvate inhibition of total release during 60 s of reperfusion; 100 mM pyruvate inhibited total postischemic ROS release by ϳ25%, and 5 mM pyruvate inhibited ϳ80% of total ROS release. Data are single values from 4 different experiments. maximum inhibition of homogenate ROS formation due to NADHox (Fig. 2) . Figure 4 and Table 1 show that postischemic ROS release was markedly stimulated by perfusate L-lactate, in sharp contrast to the inhibition by pyruvate. With physiological levels (1-2 mM) of L-lactate, peak postischemic ROS release increased by ϳ100%, or twofold, relative to preischemic release (Fig. 4) ; with 5 mM L-lactate, peak postischemic ROS release increased further, about threefold. For comparison, an equimolar 5 mM pyruvate reduced peak ROS release to ϳ10% according to Fig. 3 , a nearly 30-fold difference compared with the stimulation by L-lactate. Figure 5 shows that L-lactate also markedly and dose dependently stimulated basal and preischemic ROS release. ROS release more than doubled at Ն10 mM L-lactate. Figure 6 shows that perfusate pyruvate effectively and dose dependently inhibited the lactate (10 mM)-stimulated cardiac ROS formation: at the low physiological concentration of 0.3 mM, pyruvate inhibited ROS formation by ϳ30%. At cardioprotective levels (1-5 mM), pyruvate inhibited the lactate-induced ROS formation by ϳ40%.
To test whether endothelial X/XO contributed to guinea pig cardiac ROS release, we added the X/XO inhibitor oxypurinol (0.1-0.5 mM) to the perfusate. Oxypurinol inhibited Ͼ80% activity of isolated XO (see METHODS) but did not measurably affect the lactate (10 mM)-stimulated formation of ROS from the perfused hearts (Fig. 7) .
Pyruvate has the intramolecular configuration of an ␣-ketomonocarboxylate. This is a reactive keto-enol configuration that has the potential to scavenge H 2 O 2 and possibly other ROS nonenzymatically. This cellfree mechanism is effective with millimolar pyruvate and is independent of cellular redox systems (e.g., Ref. 6). To determine whether millimolar pyruvate directly scavenged ROS as measured by our ESR technique, we used the in vitro X/XO system as a O 2 Ϫ ⅐ generator in the absence and presence of 5-10 mM pyruvate or L-lactate. Table 2 shows that pyruvate or L-lactate had no Table 1 ). Arrows indicate start of reperfusion after 5 min of zero-flow ischemia. In a subset of different experiments, the stimulating effects of L-lactate on basal and ischemia-reperfusion-induced formation of reactive oxygen species (ROS) in isolated guinea pig hearts were verified for 1 and 10 mM L-lactate. Ischemia-reperfusion indicates peak ROS formation values during reperfusion. Effects of blocking mitochondrial pyruvate uptake by ␣-cyano-3-hydroxycinnamate. Hearts were perfused with 2 mM pyruvate (in the presence of 5 mM glucose) in the presence and absence of 0.5 mM ␣-cyano-3-hydroxycinnamate to inhibit mitochondrial pyruvate uptake (3) . Under these conditions, ␣-cyano-3-hydroxycinnamate reduces mitochondrial pyruvate oxidation by Ϸ80% without inhibiting pyruvate sarcolemmal transport or cytosolic pyruvate metabolism (3, 17, 25) . In terms of ROS formation, we observed that ␣-cyano-3-hydroxycinnamate did not appreciably alter preischemic ROS release [2.42 (control) vs. 2.17 mol/min (␣-cyano-3-hydroxycinnamate), n ϭ 2]. In agreement with Fig. 3 , peak postischemic ROS release was markedly inhibited by 2 mM pyruvate, increasing only slightly (19%) in the 2 mM pyruvate-perfused precinnamate controls. A quantitatively similar inhibition was found in the presence of ␣-cyano-3-hydroxycinnamate, where postischemic ROS release remained similarly attenuated, increasing by only 22% (mean of n ϭ 2). Thus disabling mitochondrial pyruvate uptake in the intact heart did not appreciably change the potency of pyruvate as an inhibitor of postischemic ROS production. This is consistent with a predominantly extramitochondrial mechanism of pyruvate as an inhibitor of superoxide formation in the heart under the present conditions.
In a separate series of experiments, we demonstrated the lack of effects of millimolar pyruvate on superoxide formation by X/XO as detected by ESR (see Table 2 ).
DISCUSSION
This is the first report delineating the full doseresponse relations between antioxidant pyruvate and cardiac NADHox activity or postischemic ROS production, respectively, in guinea pig hearts. The main subcellular site for this antioxidant effect of pyruvate appeared to be cytoplasmic. This was indicated by the inability of ␣-cyano-3-hydroxycinnamate, a selective inhibitor of mitochondrial pyruvate uptake (3), to disable pyruvate as an antioxidant with regard to cardiac ROS formation. Such antioxidant effects differ mechanistically from the energetic, inotropic, anaplerotic, and allosteric enhancements at the pyruvate dehydrogenase, all of which are thought to require mitochondrial uptake of pyruvate (4, 15, 17, 18, 24) . Furthermore, our new ROS inhibition data extend previous reports showing that pyruvate can raise the level of Values are means Ϯ SE; n ϭ 4. Lack of nonenzymatic scavenging by pyruvate or L-lactate of superoxide radicals generated by a xanthine/xanthine oxidase system. Xanthine oxidase (XO) induced formation of ROS in the presence of xanthine (200 M) and pyruvate or lactate. Control, absence of pyruvate or lactate; NA, not analyzed.
cardiac GSH (25) , the natural cellular antioxidant. Also, on the basis of the intramolecular ␣-keto-configuration of pyruvate, we reported earlier that millimolar pyruvate could protect thiol-containing ATPases in cell-free systems against H 2 O 2 -induced inactivation (6) . However, such direct nonenzymatic scavenger effects did not appear to play a role under the present conditions, because 5-10 mM pyruvate did not measurably inhibit ROS formation by a O 2 Ϫ ⅐ generator based on the NADH-and LDH-free X/XO system (Table 2).
Consistent with a significant extramitochondrial NADH-linked mechanism of ROS formation in the guinea pig heart, L-lactate, the physiological redox antagonist of pyruvate, markedly stimulated both basal and postischemic ROS production. Threshold doses for lactate stimulation of ROS were near its physiological level of 1 mM. Thus, all in all, our results are in harmony with the concept that the extracellular pyruvate/L-lactate system can substantially modulate cardiovascular NADHox activity and hence ROS production via a mechanism(s) involving cytosolic NADH (19) .
Pyruvate as a cytosolic antioxidant. It may seem puzzling that pyruvate, known as the chief oxidant in the LDH reaction, functions as an antioxidant in the cytoplasm. Recalling, however, that in accordance with mass-action principles, pyruvate shifts the LDH equilibrium toward L-lactate at the expense of cytoplasmic
, it is clear that pyruvate reduces available free cytosolic NADH. Extramitochondrial NADH is substrate and electron donor in the membrane-associated NADHox activity, which suggests the mechanism for the observed pyruvate-induced reduction of ROS via the LDH-linked NADH. Thus redox control of the tissue NADHox activity is intimately linked to the LDH equilibrium and hence the pyruvate-L-lactate redox couple.
ROS formation in crude homogenates, mainly representing NADHox activity, proved strikingly sensitive to exogenous pyruvate (Fig. 2) . Even at the very small dose of 50 M, which is below the normal plasma pyruvate range of 100-200 M, pyruvate significantly inhibited NADHox activity by 10% in cardiac homogenates and up to 30% in aorta or liver homogenates. Kinetic analyses of these data revealed that the halfmaximal inhibition of NADHox activity occurred with physiological pyruvate concentrations near 100 M. With respect to ROS release in postischemic hearts (reflecting metabolic flux through the intact in situ NADHox system), pyruvate was somewhat less effective. Whereas 100 M pyruvate inhibited postischemic ROS release by ϳ25% (Fig. 3) , the estimate for the half-maximal inhibitory dose was 0.81 Ϯ 0.001 mM, about four-to eightfold the physiological levels between 0.1 and 0.2 mM. Nevertheless, our findings suggest that pyruvate could markedly and effectively inhibit NADHox-linked ROS (superoxide) production in the cardiovascular system even at low physiological concentrations. Similarly, in inflamed knee joint synovial and other biofluids, physiological doses of pyruvate protect against H 2 O 2 and hydroxyl radicals (10, 22) .
On the other hand, our estimates predict that exogenous pyruvate, even when used at extremely high concentrations of Ն10 mM, fails to fully inhibit cardiac, aortic, or hepatic tissue NADHox activities (Fig. 2) . This result is in certain contrast to earlier observations demonstrating that 5-10 mM pyruvate fully prevented H 2 O 2 -induced thymocyte and endothelial apoptosis (Ref. 23 and unpublished observations), completely normalized postischemic cardiac energetics and left ventricular pressure development (4), fully prevented metabolic acidosis and delayed cerebral death in porcine hemorrhagic shock (20) , and strongly improved cardiac performance in patients with chronic heart failure (9). Whether these differences in analytical NADHox/ROS parameters versus physiological and clinical beneficial outcomes reflect different sites and mechanisms of action remains to be elucidated.
Disabling pyruvate entry into the mitochondria did not affect the antioxidant potential of pyruvate in terms of the NADHox and ROS parameters (Figs. 2 and 3); this could be inferred from the lack of effect of ␣-cyano-3-hydroxycinnamate in a dose that is known to selectively inhibit ϳ80% of mitochondrial pyruvate uptake in the guinea pig heart. In contrast, the same or comparable experimental conditions have been shown to blunt the pyruvate-induced enhancement of myocardial energetics and the metabolic inotropy of this compound as well (15) (16) (17) (18) . Metabolic strategies targeting mitochondrial energetics and cellular function seem to require 1-5 mM pyruvate for maximum effectiveness (4, 9, 13, 17) , doses that are 10-to 50-fold the normal pyruvate plasma levels. Because such high pyruvate concentrations also oxidize the cytosolic NADH system, they would combine salutary redox and antioxidant effects in the cytoplasm with the energetic and inotropic improvements mediated by the mitochondria. (Fig. 2) and/or the 25% attenuation of postischemic ROS production by 100 M pyruvate (Fig. 3) was not directly proven nor was it excluded. Any pyruvate-induced [NADH] ϩ [H ϩ ] consumption in the cytoplasm would reduce the availability of NADH for NADHox, which would inhibit flux through the oxidase system and reduce superoxide formation. Alternatively, low doses of pyruvate could reduce superoxide formation via the monocarboxylate transporter on the cell membrane, a mechanism independent from metabolic redox effects. Pyruvate and L-lactate are known to compete for myocardial uptake and release via the monocarboxylate transport protein, but pyruvate has an ϳ5-to 10-fold higher affinity to the transporter than L-lactate. This renders pyruvate an effective and natural inhibitor of myocardial Llactate uptake; preliminary data place the inhibitor constant (K i ) for pyruvate at Ϸ100 M (unpublished observations), i.e., into the range of concentrations where we obtained measurable inhibitions of NADHox and ROS formation. Such transport competition may be particularly useful for the heart in vivo, because it is permanently perfused with ϳ0.2 mM pyruvate at 1-10 mM L-lactate.
Only supraphysiological doses of pyruvate (Ն5 mM) oxidize the cytosolic [NAD ϩ ]/[NADH] ratio by orders of magnitude (2, 5, 17) . Such massive cytosolic oxidation greatly reduces the reductive potential of NADH at the catalytic sites of (lactate) dehydrogenases and hence at those of competing NADHox systems. Conversely, a substantially lower [NAD ϩ ]/[NADH] ratio due to excess L-lactate (Ն10 mM) would predict large increases in steady-state levels of ROS due to NADHox activity; these predicted opposite effects of high pyruvate versus high lactate are consistent with the ROS data in Figs. [3] [4] [5] [6] .
No role for GSH? High pyruvate can strengthen antioxidant defenses of the myocardium by raising the GSH/GSSG ratio (25) . This reductive pyruvate effect on the GSH system is mechanistically unrelated to the oxidation of [NAD ϩ ]/[NADH] in the cytosol. It is thought that the GSH/GSSG concentration ratio rises in response to a pyruvate-induced accumulation of a citrate (3, 25) that is an allosteric inhibitor of phosphofructokinase (PFK). The resulting glucose 6-phosphate accumulation upstream of PFK provides substrate pressure at the glucose-6-phosphate dehydrogenase; this enzyme is rate limiting for metabolic flux through the pentose phosphate shunt that provides NADPH for reductive syntheses as well as the reduction of GSSG to GSH. The pyruvate-induced myocardial citrate accumulation is greatly dependent on mitochondrially mediated anaplerosis, as ␣-cyano-3-hydroxycinnamate strongly inhibits this pyruvate effect (25) . In contrast, ␣-cyano-3-hydroxycinnamate did not disable pyruvate as an inhibitor of postischemic cardiac ROS formation, suggesting that the GSH system was not the first line of defense against superoxide formation by the NADHox under the present conditions.
